abstract |
Pharmaceutical combinations comprising as compound A at least one compound from the group of angiogenesis inhibitors of general formula (I) and as compound B at least one compound from the group of histone deacetylase inhibitors (HDAC) of general formula (Il) and their use for the treatment of different diseases resulting by persistent angiogenesis, are described. |